Literature DB >> 24658675

[Differences in sociodemographic characteristics, health, and health service use of children and adolescents according to their health insurance funds].

F Hoffmann1, C J Bachmann.   

Abstract

Differences in the socioeconomic characteristics and morbidity between members of German private and statutory health insurance funds and also between several statutory health insurances have been shown for adults. We used data from the National Health Survey for Children and Adolescents (KiGGS) to study differences in sociodemographic characteristics, health risks, morbidity, and health service use in child and adolescent insurants of different types of health insurance funds (Ersatzkasse, Allgemeine Ortskrankenkasse, Betriebskrankenkasse , Innungskrankenkasse, other statutory health insurance funds, private health insurance). Differences in the proportion of respondents with a migration background, somatic diseases, psychopathological problems, and contact with a dentist between the different health insurance fund types were found. These results should be considered in studies on health inequalities, which often focus solely on differences between statutory and private health insurance. Our results are also of relevance for health services research using the claims data of health insurance funds.

Entities:  

Mesh:

Year:  2014        PMID: 24658675     DOI: 10.1007/s00103-013-1916-x

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  19 in total

1.  In Reply.

Authors:  Christian J Bachmann; Alexandra Philipsen; Falk Hoffmann
Journal:  Dtsch Arztebl Int       Date:  2017-06-23       Impact factor: 5.594

2.  Determination of psychotropic use in children and adolescents from a prescription database: methodological issues.

Authors:  Christian J Bachmann; Falk Hoffmann
Journal:  Psychopharmacology (Berl)       Date:  2014-08-15       Impact factor: 4.530

3.  Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012.

Authors:  Christian J Bachmann; Thomas Lempp; Gerd Glaeske; Falk Hoffmann
Journal:  Dtsch Arztebl Int       Date:  2014-01-17       Impact factor: 5.594

4.  [Pain medication in nursing home residents with and without cancer. Most frequently with metamizole].

Authors:  J Schulze; M H Freitag; G Glaeske; G Schmiemann; F Hoffmann
Journal:  Schmerz       Date:  2015-07       Impact factor: 1.107

5.  Adjusting selection bias in German health insurance records for regional prevalence estimation.

Authors:  Ralf Thomas Münnich; Jan Pablo Burgard; Joscha Krause
Journal:  Popul Health Metr       Date:  2019-08-27

6.  ADHD in Germany: Trends in Diagnosis and Pharmacotherapy.

Authors:  Christian J Bachmann; Alexandra Philipsen; Falk Hoffmann
Journal:  Dtsch Arztebl Int       Date:  2017-03-03       Impact factor: 5.594

7.  Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011.

Authors:  Carsten Schröder; Michael Dörks; Bianca Kollhorst; Tilo Blenk; Ralf W Dittmann; Edeltraut Garbe; Oliver Riedel
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-09-13       Impact factor: 4.785

8.  Psychopharmacological Prescriptions in Children and Adolescents in Germany.

Authors:  Sascha Abbas; Peter Ihle; Jürgen-Bernhard Adler; Susanne Engel; Christian Günster; Roland Linder; Gerd Lehmkuhl; Ingrid Schübert
Journal:  Dtsch Arztebl Int       Date:  2016-06-06       Impact factor: 5.594

9.  Trends in psychopharmacologic treatment of tic disorders in children and adolescents in Germany.

Authors:  Christian J Bachmann; Veit Roessner; Gerd Glaeske; Falk Hoffmann
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-06-03       Impact factor: 4.785

10.  [Long-term opioid therapy of non-cancer pain : Prevalence and predictors of hospitalization in the event of possible misuse].

Authors:  W Häuser; T Schubert; N Scherbaum; T Tölle
Journal:  Schmerz       Date:  2018-12       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.